China is considering price controls on drugs produced byforeign-invested companies, Huang Jinfu, a vice director of the department of Comprehensive Economy at the State Pharmaceutical Administration, has told a securities conference, reports Reuters.
When these companies were first set up they could set their own prices, but this was not fair, he said. Foreign drug prices are much higher than domestic ones, and some of the latter are already controlled by the central government or local authorities. Of China's more than 3,000 drug-related firms, 20%-30% are losing money, he said. The central government plans to promote well-known products, improve management and create large-scale enterprises to boost the industry.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze